# US 2012/0083498 A1 · Modulators of Viral Transcription, and Methods and Compositions Therewith

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0083498 A1
- Document ID: US20120083498A1
- Status: Published application
- Kind: A1
- Application number: 13/162,832
- Filed: 2011-06-17
- Published: 2012-04-05
- Earliest claimed: 2010-06-17
- Inventors: Fatah Kashanchi
- Web page: https://patentgrep.com/patent/US20120083498A1

## CPC

- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/18: for HIV
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Processes to treat human immunodeficiency virus (HIV) infection are included.

## Claims

### Claim 1

A process to treat human immunodeficiency virus (HIV) infection comprising administering to a subject a therapeutically effective amount of a viral transcription modulator, a pharmaceutically acceptable salt thereof or prodrug thereof, the viral transcription modulator comprising the structure:
wherein at least one of R1, R2, and R3 is a hydrocarbon.

### Claim 2 (depends on 1)

The process of claim 1, wherein said viral transcription modulator includes at least one of CR8#13 (BJFP1154), MRT3-033, MRT3-028, MRT3-012, MRT3-038, MRT3-041, MRT3-039, MRT3-024, and MRT3-040.

### Claim 3 (depends on 1)

The process of claim 1, wherein said viral transcription modulator includes CR8#13 (BJFP1154).

### Claim 4 (depends on 0)

The process of claim 0, wherein said viral transcription modulator has an IC50 between approximately 1 nM to approximately 1000 nM.

### Claim 5 (depends on 0)

The process of claim 0, wherein said viral transcription modulator has an IC50 below approximately 50 nM.

### Claim 6 (depends on 5)

The process of claim 5, wherein said viral transcription modulator has an IC50 between approximately 10 nM.

### Claim 7 (depends on 1)

The process of claim 1, wherein said subject includes at least one of a pediatric subject, a gravid subject, an adult subject and a lactating subject.

### Claim 8 (depends on 1)

The process of claim 1, further comprising administering at least one of a nucleoside reverse transcriptase inhibitor, a nucleotide reverse transcriptase inhibitor, a non-nucleoside reverse transcriptase inhibitor, a protease inhibitor, an integrase inhibitor, an entry inhibitor, and a maturation inhibitor.